Malaria – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Malaria Market Outlook

Thelansis’s “Malaria Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Malaria treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Malaria Overview

Malaria is an acute febrile illness that arises from the transmission of Plasmodium parasites through the bites of infected female Anopheles mosquitoes. In humans, five parasite species are capable of causing malaria, with P. falciparum and P. vivax posing the most significant risk. P. falciparum is Africa's most prevalent and deadliest parasite species, while P. vivax dominates in most countries outside of sub-Saharan Africa. The onset of malaria symptoms, which include fever, headache, and chills, usually occurs 10-15 days after the infective mosquito bite. These symptoms can be mild and difficult to recognize as malaria. However, if left untreated, P. falciparum malaria can quickly progress to severe illness and death within 24 hours. Fever is a hallmark symptom of malaria that is triggered by the release of parasites every 2 to 3 days, depending on the Plasmodium species. High parasite burdens can result in severe and life-threatening malaria, causing hemolysis and severe anemia, or end-organ damage due to vascular adherence of infected erythrocytes and micro occlusion.

• Annually, estimated 247 million cases of malaria worldwide.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: